Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data

Amedeo Ferdinando Capetti, Maria Vittoria Cossu, Gaetana Sterrantino, Giorgio Barbarini, Simona Di Giambenedetto, Giuseppe Vittorio De Socio, Giancarlo Orofino, Antonio Di Biagio, Benedetto M. Celesia, Stefano Rusconi, Barbara Argenteri, Giuliano Rizzardini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

21 Citazioni (Scopus)


Background: Data from clinical studies confirm the efficacy of switching to dolutegravir (DTG) plus rilpivirine (RPV) in selected patients. Objective: The primary objective is to report the 96-week virological suppression in our cohort, assessing the durability of this strategy in complicated situations. The secondary objective is to describe the safety and metabolic profile. Methods: All patients who had switched to DTG plus RPV between October 1, 2014, and September 30, 2015, were analyzed using a retrospective-prospective design, approved by ethics committees. Routine metabolic, immunological, and virological data were regularly sent to the coordinating center. Viral control was classified as HIV-1 RNA ≥50 copies/mL, 1 to 49 copies/mL, or undetectable (no virus detected [NVD]). Results: We followed 145 patients for a median of 101 weeks. The median age was 52 years; 31.7% were women, and 9.6% non-Caucasian; 50.3% had failed at least 1 antiretroviral regimen; and 15% had ≥50 copies/mL at baseline. The reasons for switching were as follows: simplification (51.7%), toxicity (36.5%), drug-drug interactions (6.9%), persistent low-level viremia (3.0%), nonadherence (2.1%), and viral failure (1.4%). By week 96, seven patients dropped out. At week 96, none had ≥50 HIV-1 RNA copies/mL, 138 (95.2%) had <50 copies/mL, and 123 (84.8%) had NVD. The low- to high-density lipoprotein cholesterol (LDL-C/HDL-C) ratio decreased significantly (P = 0.04). Of the 287 baseline altered laboratory parameters, 32.7% normalized by week 96. Serum glucose and total- and LDL-cholesterol normalization were statistically significant. Conclusions: Switching to DTG plus RPV improved viral suppression and LDL-C/HDL-C ratio.
Lingua originaleEnglish
pagine (da-a)740-746
Numero di pagine7
Stato di pubblicazionePubblicato - 2018


  • Pharmacology (medical)
  • adverse drug reactions
  • antiretrovirals
  • drug utilization
  • metabolism
  • pharmacoeconomics


Entra nei temi di ricerca di 'Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data'. Insieme formano una fingerprint unica.

Cita questo